Story · Medicine & Biotech

StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

1 outlet · first reported by GEN Genetic Engineering News 3d ago

Coverage, in order

  1. 3d ago
    GEN Genetic Engineering News indie randomized trial
    StockWatch: Nurix Nosedives as Sanofi Halts Phase I Immunology Candidate

    Nurix Therapeutics (Nasdaq: NRIX) suffered its worst one-day loss as a public company Wednesday when Sanofi (Euronext Paris: SAN and Nasdaq: SNY) terminated development of the Phase I immunology candidate SAR448272 (NX-3911)—a key program of the companies’ nearly seven-year, up to $ 2.5 billion…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.